Acne vulgaris is one of the most common global skin diseases, affecting 40 to 50 million people in the United States. Patients have equated their condition as comparable to other serious diseases, such as diabetes, epilepsy, asthma and arthritis. Pharmaceutical products for the treatment of acne represent a large global market of approximately $4.0 billion in 2013 sales, according to IMS MIDAS.

Acne is characterized by comedones, pustules, and, potentially, scarring and is the result of 4 primary pathogenic factors:

  • Excess sebum production by sebaceous gland
  • P. acnes follicular colonization
  • Release of inflammatory mediators
  • Altered follicular keratinization

Current treatments include: topical products such as antimicrobials and retinoids that often produce only modest therapeutic benefits and systemic therapies that have been more effective, but are also associated with significant side effects.  Given the lack of innovation in the research and development of new dermatology products, we believe the limited number of treatment options approved for acne severely underserves dermatologists and their patients.